CAJ | 학술논문

目的：评价丝裂霉素与表柔比星浅表性膀胱灌癌（ SBC ）术后灌注化疗疗效及安全性。方法对2011-04-2013-01收治的SBC术后患者78例进行回顾分析，术后丝裂霉素膀胱灌注化疗者31例，灌注表柔比星者47例，比较2组灌注化疗的疗效及不良反应。结果丝裂霉素组，术后中位随访12.6个月，随访期间肿瘤复发率为16.1％（5/31）；表柔比星组，随访13.2个月，复发率为14.7％（7/47），2组复发风险比较（ HR＝1.02）差别无统计学意义（ P＞0.05）。丝裂霉素组与表柔比星组局部药物不良反应发生率分别为54.8％（17/31），57.4％（27/47），差别无统计学意义（ P＞0.05）。结论丝裂霉素与表柔比星用于SBC术后灌注化疗疗效及安全性无明显差别。
목적：평개사렬매소여표유비성천표성방광관암（ SBC ）술후관주화료료효급안전성。방법대2011-04-2013-01수치적SBC술후환자78례진행회고분석，술후사렬매소방광관주화료자31례，관주표유비성자47례，비교2조관주화료적료효급불량반응。결과사렬매소조，술후중위수방12.6개월，수방기간종류복발솔위16.1％（5/31）；표유비성조，수방13.2개월，복발솔위14.7％（7/47），2조복발풍험비교（ HR＝1.02）차별무통계학의의（ P＞0.05）。사렬매소조여표유비성조국부약물불량반응발생솔분별위54.8％（17/31），57.4％（27/47），차별무통계학의의（ P＞0.05）。결론사렬매소여표유비성용우SBC술후관주화료료효급안전성무명현차별。
Objective To evaluate the clinical efficacy and adverce drug reaction ( ADR ) for epirubicin and mitomycin bladder instillation chemotherapy in the treatment of superficial bladder cancer ( SBC ).Methods Seventy-eight cases of postsurgical SBC recruited from Apr 2011 to Jan 2013 in our hospital retrospectively.Of the 78 subjects , 31 patients were treated by mitomycin and other 47 cases were treated by epirubicin.The clinical efficacy and ADR of the two groups were recor-ded and compared.Results The median follow-up period of mitomy-cin group was 12.6 months with a recurrence rate of 16.1%( 5/31 ).And the median follow -up period of epirubicin group was 13.2 months with a recurrence rate of 14.7%(7/47).No statistical difference of re-currence of hazard ratio ( HR=1.02 ) was found between the two groups ( P>0.05).Conclusion There were no statistical difference for epiru-bicin and mitomycin bladder instillation chemotherapy in the treatment of superficial bladder cancer.